Barclays
PRTK

Barclays’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Barclays’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,952
Closed -$24K – 5380
2022
Q1 		$24K Sell
7,952
-51,495
-87% -$194K ﹤0.01% 4399
2021
Q4 		$267K Buy
59,447
+39,919
+204% +$189K ﹤0.01% 3461
2021
Q3 		$94K Buy
19,528
+13,272
+212% +$73.1K ﹤0.01% 3928
2021
Q2 		$42K Sell
6,256
-62,654
-91% -$507K ﹤0.01% 4218
2021
Q1 		$486K Buy
68,910
+22,450
+48% +$162K ﹤0.01% 3197
2020
Q4 		$291K Sell
46,460
-5,558
-11% -$32.7K ﹤0.01% 3560
2020
Q3 		$281K Sell
52,018
-2,528
-5% -$12.5K ﹤0.01% 3624
2020
Q2 		$285K Buy
54,546
+43,515
+394% +$193K ﹤0.01% 3795
2020
Q1 		$34K Sell
11,031
-21,968
-67% -$81K ﹤0.01% 5438
2019
Q4 		$133K Buy
32,999
+16,543
+101% +$57.4K ﹤0.01% 5309
2019
Q3 		$71K Sell
16,456
-4,886
-23% -$19.5K ﹤0.01% 5723
2019
Q2 		$85K Buy
21,342
+11,906
+126% +$56.6K ﹤0.01% 5811
2019
Q1 		$51K Buy
9,436
+6,935
+277% +$44.8K ﹤0.01% 5858
2018
Q4 		$13K Sell
2,501
-9,474
-79% -$71.9K ﹤0.01% 6083
2018
Q3 		$117K Buy
11,975
+9,611
+407% +$96.9K ﹤0.01% 5417
2018
Q2 		$24K Sell
2,364
-3,543
-60% -$40.1K ﹤0.01% 6084
2018
Q1 		$77K Sell
5,907
-12,698
-68% -$189K ﹤0.01% 5579
2017
Q4 		$333K Buy
18,605
+52
+0.3% +$1.08K ﹤0.01% 4240
2017
Q3 		$466K Buy
18,553
+3,155
+20% +$73.4K ﹤0.01% 3699
2017
Q2 		$370K Sell
15,398
-1,648
-10% -$36.4K ﹤0.01% 3818
2017
Q1 		$328K Buy
17,046
+6,936
+69% +$109K ﹤0.01% 3828
2016
Q4 		$155K Sell
10,110
-14,414
-59% -$187K ﹤0.01% 4420
2016
Q3 		$319K Buy
24,524
+19,090
+351% +$253K ﹤0.01% 3598
2016
Q2 		$76K Buy
+5,434
New +$80K ﹤0.01% 4589
2015
Q4 		– Sell
-64
Closed -$1K – 6733
2015
Q3 		$1K Sell
64
-169
-73% -$4.21K ﹤0.01% 6635
2015
Q2 		$6K Buy
+233
New +$6.61K ﹤0.01% 6380
2013
Q3 		– Sell
-986
Closed -$36K – 7661
2013
Q2 		$36K Buy
+986
New +$42.3K ﹤0.01% 6531

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FIG
Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Barclays's PRTK Position: Q2 2022 in Review

Barclays sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2022, closing a stake of 7,952 shares — an estimated $24K sold.

Barclays first reported a position in PRTK in Q2 2013 and held it in 27 quarters. The position peaked at $486K in Q1 2021. 84 funds tracked by Wall St. Rank hold PRTK as of Q2 2022.

  • Barclays reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 7,952 Paratek Pharmaceuticals, Inc. shares in Q2 2022, an estimated $24K.
  • Barclays first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 27 quarters.
  • Barclays's Paratek Pharmaceuticals, Inc. position peaked at $486K in Q1 2021.
  • 84 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.